Clinical trial NCT04202055: Immunologic Biomarker Profile of Cerebrospinal Fluid
Official title: Immunologic Biomarker Profile of Cerebrospinal Fluid
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Multiple Sclerosis
Neuromyelitis Optica
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
First posted: 2019-12-17
Enrollment: 165
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Samples stored from the NOMADMUS cohort in the OFSEP collection and the NEURO collection from the Centre de Collections Biologiques Hospitalières

Brief summary: The aim of this study was the describe the Immunologic biomarker profile of cerebrospinal fluid in multiple sclerosis patients


Eligibility criteria: Inclusion Criteria:

* patients who have had neuromyelitis ptica with anti-AQP4 antibodies, or anti- Myelin Oligodendrocyte Glycoprotein antibodies, or double seronegative antibodies.
* Neuromyelitis Optica patients have been prospectively included in the OFSEP collection
* Multiple sclerosis patients, isolated myelitis or optic neuritis patients, and symptomatic controls whose samples will come from the "NEURO" collection of the Hospital Biological Collections Center,
* Patients have given their free consent for use of their samples in research

Primary outcomes:
measure: Level of glial fibrillar acidic protein in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein
timeFrame: Baseline
measure: Level of chitinase-3-like protein 1 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein
timeFrame: Baseline
measure: Level of neurofilament in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein
timeFrame: Baseline
measure: Level of Interleukin-6 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein
timeFrame: Baseline
measure: Level of Interleukin-8 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein
timeFrame: Baseline
measure: Level of C-X-C motif ligand (CXCL-13) in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein
timeFrame: Baseline
measure: Level of Matrix metalloproteinase-9 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein
timeFrame: Baseline
measure: Level of Soluble CD27 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein
timeFrame: Baseline
measure: Level of Interleukin 10 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein
timeFrame: Baseline
measure: Level of Interleukin 17A in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein
timeFrame: Baseline
measure: Level of Interleukin 1B in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein
timeFrame: Baseline
measure: Level of monocyte chemoattractant protein-1 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein
timeFrame: Baseline
measure: Level of soluble intercellular adhesion molecule-1 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein
timeFrame: Baseline
measure: Level of soluble vascular cell adhesion molecule-1 in cerebrospinal fluid in patients with Neuromyelitis Optica with anti- Myelin Oligodendrocyte Glycoprotein
timeFrame: Baseline
Secondary outcomes:
measure: Level of glial fibrillar acidic protein in cerebrospinal fluid in each group
timeFrame: Baseline
measure: Level of chitinase-3-like protein 1 in cerebrospinal fluid in each group
timeFrame: Baseline
measure: Level of neurofilament in cerebrospinal fluid in each group
timeFrame: Baseline
measure: Level of Interleukin-6 in cerebrospinal fluid in each group
timeFrame: Baseline
measure: Level of Interleukin-8 in cerebrospinal fluid in each group
timeFrame: Baseline
measure: Level of C-X-C motif ligand (CXCL-13) in cerebrospinal fluid in each group
timeFrame: Baseline
measure: Level of Matrix metalloproteinase-9 in cerebrospinal fluid in each group
timeFrame: Baseline
measure: Level of Soluble CD27 in cerebrospinal fluid in each group
timeFrame: Baseline
measure: Level of Interleukin 10 in cerebrospinal fluid in each group
timeFrame: Baseline
measure: Level of Interleukin 17A in cerebrospinal fluid in each group
timeFrame: Baseline
measure: Level of Interleukin 1B in cerebrospinal fluid in each group
timeFrame: Baseline
measure: Level of monocyte chemoattractant protein-1 in cerebrospinal fluid in each group
timeFrame: Baseline
measure: Level of soluble intercellular adhesion molecule-1 in cerebrospinal fluid in each group
timeFrame: Baseline
measure: Level of soluble vascular cell adhesion molecule-1 in cerebrospinal fluid in each group
timeFrame: Baseline
Other outcomes:
Locations:
city: Nîmes
country: France
facility: CHU de Nimes
Study officials:
affiliation: CHU Nimes
name: Eric Thouvenot
role: PRINCIPAL_INVESTIGATOR
References: